Renin-Angiotensin System Intervention to Prevent In-Stent Restenosis
| Autor: | Felix Zijlstra, Adriaan A. Voors, René A. Tio, Wiek H. van Gilst, Bas Langeveld, Anton J.M. Roks |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Placebo-controlled study Target vessel revascularization Angiotensin-Converting Enzyme Inhibitors Coronary Restenosis Renin-Angiotensin System Restenosis Intervention (counseling) Internal medicine Renin–angiotensin system medicine Animals Humans cardiovascular diseases Pharmacology Clinical Trials as Topic business.industry Stent equipment and supplies medicine.disease surgical procedures operative Cardiology Stents In stent restenosis Cardiology and Cardiovascular Medicine business Angiotensin II Type 1 Receptor Blockers Angiotensin II Type I Receptor Blockers Angioplasty Balloon |
| Zdroj: | Journal of Cardiovascular Pharmacology. 45:88-98 |
| ISSN: | 0160-2446 |
| DOI: | 10.1097/00005344-200501000-00015 |
| Popis: | The occurrence of in-stent restenosis is a major drawback of percutaneous transluminal coronary angioplasty with stent placement. Target vessel revascularization is necessary in 15% of patients who receive a stent. Recent advances in the development of drug-eluting stents have reduced these numbers tremendously. However refinement of antirestenotic therapies remains obligatory. The emerging interest in more physiological antirestenotic therapies might unchain an interest in the well-known inhibitors of the rennin-angiotensin system (RAS), the angiotensin-converting enzyme inhibitors, and the angiotensin II type I receptor blockers. Contradictory results overshadow the discussion of whether intervention in the RAS could prevent in-stent restenosis. This review discusses the pathophysiology of in-stent restenosis, the role of the RAS in in-stent restenosis, and the possible role of RAS intervention in the prevention of in-stent restenosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|